Cardiac Markers Book

	Foreword
	Preface
	Contributors
1	Early Detection of Myocardial Necrosis in the Emergency Setting and Utility of Serum Biomarkers in Chest Pain Unit Protocols	3
2	Management of Acute Coronary Syndromes	15
3	Evolution of Cardiac Markers in Clinical Trials	37
4	Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers: Practice and Promise	59
5	The Use of Cardiac Biomarkers to Detect Myocardial Damage Induced by Chemotherapeutic Agents	87
6	The Use of Biomarkers to Provide Diagnostic and Prognostic Information Following Cardiac Surgery	111
7	Cardiac Troponins: Exploiting the Diagnostic Potential of Disease-Induced Protein Modifications	125
8	Cardiac Troponin Testing in Renal Failure and Skeletal Muscle Disease Patients	139
9	Cardiac-Specific Troponins Beyond Ischemic Heart Disease	149
10	Antibody Selection Strategies in Cardiac Troponin Assays	173
11	Interferences in Immunoassays for Cardiac Troponin	187
12	Cardiac Marker Measurement by Point-of-Care Testing	199
13	Standardization of Cardiac Markers	213
14	Analytical Issues and the Evolution of Cutoff Concentrations for Cardiac Markers	231
15	Rationale for the Early Clinical Application of Markers of Ischemia in Patients with Suspected Acute Coronary Syndromes	245
16	Ischemia-Modified Albumin, Free Fatty Acids, Whole Blood Choline, B-Type Natriuretic Peptide, Glycogen Phosphorylase BB, and Cardiac Troponin	259
17	C-Reactive Protein for Primary Risk Assessment	279
18	Prognostic Role of Plasma High-Sensitivity C-Reactive Protein Levels in Acute Coronary Syndromes	291
19	Preanalytic and Analytic Sources of Variations in C-Reactive Protein Measurement	305
20	Fatty Acid Binding Protein as an Early Plasma Marker of Myocardial Ischemia and Risk Stratification	319
21	Oxidized Low-Density Lipoprotein and Malondialdehyde-Modified Low-Density Lipoprotein in Patients with Coronary Artery Disease	339
22	Pathophysiology of Heart Failure	351
23	B-Type Natriuretic Peptide: Biochemistry and Measurement	369
24	B-Type Natriuretic Peptide in the Diagnoses and Management of Congestive Heart Failure	379
25	Monitoring Efficacy of Treatment with Brain Natriuretic Peptide	397
26	N-Terminal Pro-B-Type Natriuretic Peptide	411
27	Infectious Diseases in the Etiology of Atherosclerosis and Acute Coronary Syndromes: Focus on Chlamydia pneumoniae	427
28	Polymorphisms Related to Acute Coronary Syndromes and Heart Failure: Potential Targets for Pharmacogenomics	439
	Index	461